Back to top
more

GoodRx (GDRX)

(Real Time Quote from BATS)

$6.16 USD

6.16
649,439

+0.22 (3.70%)

Updated Nov 6, 2024 11:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 45% (137 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

What to Look for in Crescent Point's (CPG) Q4 Earnings?

by Zacks Equity Research

Lower price realizations and an upward cost trajectory are likely to have dented Crescent Point Energy's (CPG) fourth-quarter results.

Countdown to GoodRx Holdings, Inc. (GDRX) Q4 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for GoodRx Holdings, Inc. (GDRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

What Will Global Partners' (GLP) Q4 Earnings Unveil?

by Zacks Equity Research

Global Partners LP (GLP) beat the Zacks Consensus Estimate for earnings in two of the last four quarters and missed in the other two.

GoodRx Holdings, Inc. (GDRX) Reports Next Week: What Awaits?

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Medtronic (MDT) in Q3 Earnings?

by Zacks Equity Research

Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.

Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Revised)

by Zacks Equity Research

Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.

Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?

by Zacks Equity Research

Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.

Encompass Health (EHC) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.

Labcorp (LH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.

Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?

by Zacks Equity Research

Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.

How Much Upside is Left in GoodRx Holdings, Inc. (GDRX)? Wall Street Analysts Think 27.83%

by Zacks Equity Research

The consensus price target hints at a 27.8% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?

by Zacks Equity Research

Cigna's (CI) fourth-quarter results are likely to reflect growth in Evernorth revenues and customer base.

STERIS (STE) Set to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) third-quarter fiscal 2024 results are likely to reflect solid performance across both the Healthcare and AST segments.

Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) fourth-quarter results are likely to reflect increased admissions and a lower average length of stay.

Earnings Estimates Rising for GoodRx Holdings, Inc. (GDRX): Will It Gain?

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

What Makes GoodRx Holdings, Inc. (GDRX) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does GoodRx Holdings, Inc. (GDRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

After Golden Cross, GoodRx Holdings, Inc. (GDRX)'s Technical Outlook is Bright

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ELV vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

Compared to Estimates, GoodRx Holdings, Inc. (GDRX) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Waters (WAT) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Waters' (WAT) Q3 results benefit from a strong Pharmaceutical market, as well as a strong contribution from the Wyatt acquisition.

Avantor, Inc. (AVTR) Q3 Earnings Meet Estimates

by Zacks Equity Research

Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 0% and 1.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

ICLR vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ICLR vs. GDRX: Which Stock Is the Better Value Option?